WELLESLEY, Mass., Oct. 24 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Robert L. Bratzler, Ph.D., Coley's President and Chief Executive Officer, plans to provide a corporate presentation at the C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31, 2006 at 9:00 a.m. at the Palace Hotel in New York, NY.
Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until November 14, 2006.
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious disease, and asthma and allergy. Coley has established a pipeline of four TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Novartis Vaccines & Diagnostics (formerly Chiron), GlaxoSmithKline and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.
Coley Pharmaceutical Group, Inc.CONTACT: Susan Hager, Senior Director, Investor Relations and CorporateCommunications of Coley Pharmaceutical Group, +1-781-431-9079,shager@coleypharma.com; or Karen L. Bergman, +1-650-575-1509,kbergman@bccpartners.com or Michelle Corral, +1-415-794-8662,mcorral@bccpartners.com, both of BCC Partners (US)
Web site: http://www.coleypharma.com/
